TY - JOUR
T1 - Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer
AU - Stone, Rebecca L.
AU - Cambron-Mellott, M. Janelle
AU - Beusterien, Kathleen
AU - Maculaitis, Martine C.
AU - Ritz, Stephanie
AU - Mulvihill, Emily
AU - Monberg, Matthew
AU - Szamreta, Elizabeth A.
AU - Amin, Suvina
AU - McLaurin, Kimmie
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit-risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk.
AB - Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit-risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk.
KW - PARP inhibitors
KW - epithelial ovarian cancer
KW - maintenance therapy
KW - patient preferences
KW - physician preferences
UR - http://www.scopus.com/inward/record.url?scp=85123969095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123969095&partnerID=8YFLogxK
U2 - 10.2217/fon-2021-0567
DO - 10.2217/fon-2021-0567
M3 - Article
C2 - 34875854
AN - SCOPUS:85123969095
SN - 1479-6694
VL - 18
SP - 491
EP - 503
JO - Future oncology (London, England)
JF - Future oncology (London, England)
IS - 4
ER -